Display options
Cite
Olvera A, Martinez JP, Casadellà M, et al. Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy . Front Immunol. 2018;8:2010doi: 10.3389/fimmu.2017.02010.
Olvera, A., Martinez, J. P., Casadellà, M., Llano, A., Rosás, M., Mothe, B., Ruiz-Riol, M., Arsequell, G., Valencia, G., Noguera-Julian, M., Paredes, R., Meyerhans, A., & Brander, C. (2017). Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy . Frontiers in immunology, 82010. https://doi.org/10.3389/fimmu.2017.02010
Olvera, Alex, et al. "Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy ." Frontiers in immunology vol. 8 (2017): 2010. doi: https://doi.org/10.3389/fimmu.2017.02010
Olvera A, Martinez JP, Casadellà M, Llano A, Rosás M, Mothe B, Ruiz-Riol M, Arsequell G, Valencia G, Noguera-Julian M, Paredes R, Meyerhans A, Brander C. Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy . Front Immunol. 2018 Jan 26;8:2010. doi: 10.3389/fimmu.2017.02010. eCollection 2017. PMID: 29472913; PMCID: PMC5810283.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2018 Jan 26;8:2010. doi: 10.3389/fimmu.2017.02010. eCollection 2017.

Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy .

Frontiers in immunology

Alex Olvera, Javier P Martinez, Maria Casadellà, Anuska Llano, Míriam Rosás, Beatriz Mothe, Marta Ruiz-Riol, Gemma Arsequell, Gregorio Valencia, Marc Noguera-Julian, Roger Paredes, Andreas Meyerhans, Christian Brander

Affiliations

  1. IrsiCaixa - AIDS Research Institute, Badalona, Barcelona, Spain.
  2. Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Vic, Barcelona, Spain.
  3. Infection Biology Group, Department of Experimental and Health Sciences, University Pompeu Fabra, Barcelona, Spain.
  4. Unitat VIH, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
  5. Institut de Química Avançada de Catalunya (IQAC-CSIC), Barcelona, Spain.
  6. Universitat Autonoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.
  7. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

PMID: 29472913 PMCID: PMC5810283 DOI: 10.3389/fimmu.2017.02010

Abstract

Glycosylation of host and viral proteins is an important posttranslational modification needed to ensure correct function of glycoproteins. For this reason, we asked whether inhibition of O-glycosylation during human immunodeficiency virus (HIV)

Keywords: O-glycosylation; benzyl-2-acetamido-2-deoxy-α-d-galactopyranoside; human immunodeficiency virus-1; infectivity; replication; viral outgrowth

References

  1. Science. 2014 Jan 3;343(6166):1235681 - PubMed
  2. J Proteome Res. 2013 May 3;12(5):2045-54 - PubMed
  3. PLoS Pathog. 2013;9(5):e1003398 - PubMed
  4. J Biol Chem. 1989 Nov 15;264(32):19271-7 - PubMed
  5. Nat Rev Microbiol. 2015 Jul;13(7):414-25 - PubMed
  6. PLoS One. 2010 Mar 10;5(3):e9490 - PubMed
  7. J Clin Microbiol. 1986 Oct;24(4):639-41 - PubMed
  8. Bioinformatics. 2014 Mar 1;30(5):614-20 - PubMed
  9. Virol J. 2012 Aug 28;9:177 - PubMed
  10. Mol Biol Evol. 2013 Apr;30(4):772-80 - PubMed
  11. Curr HIV/AIDS Rep. 2016 Feb;13(1):31-7 - PubMed
  12. Clin Exp Immunol. 1997 Oct;110(1):22-5 - PubMed
  13. J Cell Biol. 1998 Jun 15;141(6):1311-22 - PubMed
  14. PLoS One. 2015 Apr 27;10(4):e0124784 - PubMed
  15. Nat Med. 2014 Apr;20(4):425-9 - PubMed
  16. Microb Cell Fact. 2013 Sep 24;12:85 - PubMed
  17. Sci Rep. 2017 Feb 24;7:43231 - PubMed
  18. Virol J. 2006 Nov 24;3:99 - PubMed
  19. Nat Biotechnol. 2007 Dec;25(12):1407-10 - PubMed
  20. Biochimie. 2003 Mar-Apr;85(3-4):323-30 - PubMed
  21. Mol Biol Evol. 2011 Oct;28(10):2731-9 - PubMed
  22. J Virol. 2015 Dec 04;90(4):1788-801 - PubMed
  23. J Virol. 2013 Jul;87(13):7218-33 - PubMed
  24. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3699-707 - PubMed
  25. J Biol Chem. 2002 Mar 22;277(12):9825-33 - PubMed
  26. Glycoconj J. 1996 Oct;13(5):717-26 - PubMed
  27. Bioinformatics. 2014 Aug 1;30(15):2114-20 - PubMed
  28. Virol J. 2010 Oct 14;7:269 - PubMed
  29. PLoS One. 2012;7(2):e32714 - PubMed
  30. PLoS Pathog. 2014 Jul 17;10(7):e1004146 - PubMed
  31. Nat Commun. 2017 Mar 28;8:14954 - PubMed
  32. Neonatology. 2008;93(3):162-70 - PubMed
  33. J Virol. 1996 Nov;70(11):7462-70 - PubMed
  34. Science. 1997 Nov 14;278(5341):1291-5 - PubMed
  35. Biochem J. 1998 Aug 15;334 ( Pt 1):283-95 - PubMed
  36. Retrovirology. 2017 Jan 13;14 (1):2 - PubMed
  37. J Immunol. 1987 Mar 15;138(6):1719-23 - PubMed
  38. Microbes Infect. 2017 Jan;19(1):69-74 - PubMed
  39. J Clin Invest. 2016 Feb;126(2):464-72 - PubMed
  40. Curr HIV Res. 2011 Dec 1;9(8):568-78 - PubMed
  41. Curr Opin Struct Biol. 2017 Jun;44:125-133 - PubMed
  42. J Proteome Res. 2013 Mar 1;12(3):1223-34 - PubMed
  43. Sci Rep. 2015 Nov 13;5:16445 - PubMed
  44. Bioinformatics. 2015 Nov 1;31(21):3476-82 - PubMed
  45. Glycobiology. 2000 Jun;10(6):565-75 - PubMed
  46. Retrovirology. 2015 May 07;12:37 - PubMed
  47. J Biol Chem. 2003 Sep 26;278(39):37799-809 - PubMed
  48. J Proteome Res. 2014 Sep 5;13(9):4012-27 - PubMed
  49. Glycobiology. 2009 Apr;19(4):382-98 - PubMed
  50. J Virol. 2016 Jun 10;90(13):6148-58 - PubMed
  51. PLoS Biol. 2012;10(12):e1001448 - PubMed
  52. Oncol Res. 1992;4(11-12):507-15 - PubMed
  53. J Virol. 2017 Apr 13;91(9): - PubMed
  54. Virol J. 2008 May 19;5:59 - PubMed
  55. J Virus Erad. 2015 Jul 01;1(3):148-52 - PubMed
  56. J Virol. 2011 Aug;85(16):8270-84 - PubMed
  57. Open Forum Infect Dis. 2015 Aug 26;2(4):ofv123 - PubMed
  58. J Virol. 2015 Aug;89(16):8245-57 - PubMed
  59. Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7908-E7916 - PubMed
  60. AIDS. 2010 Jul 17;24(11):1625-31 - PubMed
  61. Virology. 2017 Jul;507:135-139 - PubMed
  62. Clin Infect Dis. 2010 Jul 15;51(2):233-8 - PubMed

Publication Types